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ABSTRACT



RESUM
E

Background: Evidence from clinical trials suggests a differential effect
of sex on the effectiveness and safety of direct oral anticoagulants
(DOACs) for stroke prophylaxis in atrial ﬁbrillation (AF).
Methods: This population-based cohort study examined the independent effect of sex on hemorrhage and ischemic stroke in 23,884 patients (55% females; age  66 years) with AF starting apixaban or
rivaroxaban treatment in Ontario, Canada. Patients were followed for
90 days after their DOAC prescription. Using female sex as the exposure of interest, differences in baseline characteristics were balanced
between sexes using inverse probability weights based on propensity
scores. Applying weighted modiﬁed Poisson regression, risk ratios
(RRs) were estimated for major hemorrhage, ischemic stroke/systemic embolism/transient ischemic attack (hereafter stroke),
myocardial infarction, and all-cause mortality, with males as a
reference.
Results: Females were older, had higher predicted stroke risk (based
on CHADS2 score), and had fewer comorbidities than did males. Males
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Non-valvular atrial ﬁbrillation (AF) is a common cardiac
arrhythmia among elderly patients that is associated with
increased risks for stroke and death, affecting approximately

200,000 Canadians.1-3 Oral anticoagulation (OAC) therapy is
effective in preventing ischemic strokes and other embolic
events in patients with AF,4,5 and it comprises the vitamin K
antagonist warfarin, and more recently, direct-acting oral anticoagulants (DOACs), including dabigatran, rivaroxaban,
apixaban, and edoxaban. DOACs cause rapid anticoagulation
by directly targeting clotting factors, with no need for routine
monitoring and reduced potential for food effects or drug
interactions, and serve as clinically favored alternatives to
warfarin, with similar or superior efﬁcacy.6,7 In Canada,
DOAC prescriptions in AF patients increased from 22.1% of
annual anticoagulant prescriptions in 2011 to 87.3% in 2017,
with apixaban and rivaroxaban accounting for 60% and 23%
of prescriptions in the ﬁnal year.8
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had a higher prevalence of coronary artery disease, diabetes, and
cancer, and similar predicted bleeding risk (based on HAS-BLED score).
After weighting, baseline characteristics were well balanced. The 90day risks for hemorrhage (RR 0.96; 95% conﬁdence interval [CI]
0.80-1.15; P ¼ 0.69) and stroke (RR 1.01; 95% CI 0.86-1.19; P ¼
0.94) were similar between sexes, which remained true when
assessing each DOAC separately by dosing regimen. Compared to
males, females had a lower risk for myocardial infarction (RR 0.66;
95% CI 0.52-0.84; P ¼ 0.0008), and for all-cause mortality (RR 0.76;
95% CI 0.67-0.87; P < 0.0001).
Conclusions: Our ﬁndings do not suggest an association of sex with
the 90-day risk of hemorrhage or ischemic stroke in older AF patients
prescribed apixaban or rivaroxaban.
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Sex differences in thromboembolic events among AF patients are well documented. In non-anticoagulated AF patients, female sex has been independently associated with
increased stroke risk,9-12 and risk may remain elevated despite
anticoagulant therapy, as shown for warfarin.11-13 Given the
recency of the approval of DOACs, studies evaluating sexspeciﬁc differences in their effectiveness and safety in AF patients are sparse and limited to secondary analyses of clinical
trials data. Although evidence remains conﬂicting
(Supplemental Table S1),14-18 women may have higher stroke
and/or lower bleeding risks than men. Moreover, these trials
were not designed to investigate the independent effect of sex
on DOAC-related outcomes, comprising more male and on
average younger patients than are seen in routine practice, yet
AF-related stroke risk tends to be greatest among elderly
women (age > 75 years).10,11 Accordingly, data for patients in
routine practice remain largely unexplored.
Apixaban and rivaroxaban elicit their pharmacologic effects
in a concentration-dependent manner, and factors that
signiﬁcantly alter drug concentration may inﬂuence anticoagulant response.19,20 Reduced doses are recommended in AF
patients who have clinical characteristics that may enhance
blood concentration, such as low body weight, old age, and
impaired renal function.21,22 We reported female sex as an
independent predictor of elevated apixaban concentration
among AF patients after controlling for age, weight, and
serum creatinine level,23 corroborating previous ﬁndings that
women, on average, have a 15% higher apixaban drug exposure than men.20 Elderly female patients on apixaban may be
more susceptible to bleeding or better protected from stroke,
compared to their male counterparts, whereas rivaroxaban
concentration does not appear to be inﬂuenced by sex.24
Taken together, the rising popularity of DOACs, the onaverage higher drug exposure in women, and evidence for
differential sex-dependent effects on their safety and effectiveness being limited to clinical trials data highlight the need
to assess the association of sex with DOAC-related outcomes
in AF routine care. Using propensity score weights, this study

determined whether females, compared to males, prescribed
either apixaban or rivaroxaban, differ in their 90-day risk of
major bleeding or stroke in a large population-based cohort of
elderly AF patients.
Methods
Study design
We conducted a retrospective cohort study using provincial
healthcare databases to assess sex-related differences in clinical
outcomes related to the use of rivaroxaban and apixaban in AF
patients. These databases capture health information of
Ontario, Canada residents and include patient utilization of
hospital and physician services and prescription drugs in those
age  65 years. Datasets were linked using unique identiﬁers
and analyzed at ICES Western. The use of data herein was
authorized under section 45 of Ontario’s Personal Health
Information Protection Act, which does not require research
ethics board review. This study followed the Reporting of
Studies Conducted Using Observational Routinely Collected
Data (RECORD) guidelines (Supplemental Table S2).
Study cohort
Our study cohort comprised adults aged  66 years in
Ontario, Canada. We considered all patients with a prescription of rivaroxaban or apixaban for at least 7 days between January 1, 2012 and December 31, 2017 and within
30 days of an AF diagnosis, referred to as newly treated AF.
The AF diagnosis was deﬁned based on the following codes of
the International Statistical Classiﬁcation of Diseases and
Related Health Problems (ICD-10): I4800, paroxysmal atrial
ﬁbrillation; I4801, persistent atrial ﬁbrillation; I4802, chronic
atrial ﬁbrillation; I4890, atrial ﬁbrillation, unspeciﬁed. We
looked back as far as 2002 to ensure that patients did not have
a diagnosis of AF prior to their cohort inclusion diagnosis
date. Exclusion criteria for patients were deﬁned a priori and
are listed in Figure 1.
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Patients diagnosed with AF starting an apixaban or rivaroxaban prescription
between January 1, 2012 and December 31, 2017
(n = 39,327)
Patients excluded according to the following criteria (n = 15,443):
• Missing or invalid age, sex, death date on or before time of the DOAC prescription
(index date), and/or non-Ontario resident, as data cleaning measures
• Aged 65 years and younger to avoid incomplete medication records
• Evidence of any oral anticoagulant use within 180 days prior to index date to
ensure new DOAC users
• Prescribed ≥ 2 anticoagulants on index date
• Non-eligible DOAC daily dose (apixaban ≠ 5-10 mg; rivaroxaban ≠ 15-20 mg)
• Mechanical heart valve surgery within the 5 years prior to index date
• Hospital discharge ≤ 2 days prior to the cohort entry date where the length
of stay was > 30 days

Patient cohort before weighting
Female = 13,097
Males = 10,787

Inverse
probability
weighting

Pseudo-cohort after weighting
Female = 23,821
Males = 23,698

Figure 1. Patient ﬂow diagram. AF, atrial ﬁbrillation; DOAC, direct oral anticoagulant.

Data sources and covariates
Baseline covariates, including demographics, comorbidities, prescription drugs, hospital services, and laboratory data,
were deﬁned a priori based on previous literature suggesting
an effect on outcomes studied, and they were collected along
with outcomes data using records from 9 linked databases
(Supplemental Appendix S1). Laboratory measurements of
serum creatinine level and estimated glomerular ﬁltration rate
(eGFR) were available for w45% of patients.
Exposure and outcomes
Patients were grouped as females and males for analyses
with sex as the exposure variable. Primary outcomes were
hospital encounters (hospitalization or emergency department
[ED] visit) with (i) major hemorrhage or (ii) stroke, systemic
embolism (SE), or transient ischemic attack (TIA). Secondary
outcomes were ischemic stroke or SE (excluding TIA),
myocardial infarction (MI), and all-cause mortality. Diagnostic codes used to ascertain outcomes are listed in
Supplemental Table S3. Outcomes data were collected over a
90-day period after a new rivaroxaban or apixaban prescription. This prescription date served as the index date (cohort
entry date), which was the start of follow-up. Patients were
followed until a hospital admission or ED visit with the study
outcome, death, or completion of follow-up. We chose 90

days in order to focus on acute events, and to avoid medication crossovers that may occur with DOAC use over longer
periods. In routine care, about one quarter of AF patients are
no longer adherent to their medication one year after starting
a DOAC.8 Moreover, our initial data showed that the highest
event rate occurred during the ﬁrst 90 days, compared to that
for one year, conﬁrming a previous report.25
Statistical analysis
To adjust for confounding variables in baseline characteristics between female (exposed) and male (unexposed/reference) cohorts, we used the inverse probability of treatment
weights based on propensity scores.26-28 Weights were deﬁned
as the inverse of the predicted probability of receiving the
“treatment” they received, with “treatment” herein being
unmodiﬁable sex. Speciﬁcally, propensity scores were calculated using multivariable logistic regression including 60
baseline characteristics (Supplemental Table S4) to estimate
the probability of being a female AF patient starting treatment. Propensity score-based weights were then applied to all
subjects to create synthetic weighted pseudo-cohorts of males
and females that were balanced in their baseline characteristics. These weights have been shown to produce unbiased
estimates of the average treatment effect, similar to the result
that would be obtained from a randomized controlled trial.
The use of a robust sandwich variance estimator accounts for
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the correlation induced in the data by the weighting. Standardized differences, rather than P values, were used to evaluate this balance before and after weighting, calculated as the
difference between group means relative to the pooled standard deviation; differences of  0.10 were considered to be
meaningful. Given that they are dependent on sample size, P
values may not adequately reﬂect a meaningful difference.29
Analyses were carried out on weighted cohorts. Weighted
risk ratios (RRs) with 95% conﬁdence intervals (CIs)
comparing females to males for primary outcomes were
estimated using modiﬁed Poisson regression.28 Secondary
analyses were carried out to ascertain initial ﬁndings. Poisson
regression was repeated, adjusting for dosing regimens to
account for the potential effect of a residual imbalance in
prescribed dosage between cohorts. Cox proportional hazards
regression (sensitivity analysis) was used to compare 90-day
outcomes between sexes, censoring for death. The cumulative outcome probability was plotted using the complement
of the Kaplan-Meier product limit estimator. Prespeciﬁed
subgroup analyses were performed, assessing each DOAC
separately by dosing regimen, for example, comparing females vs males on apixaban 2.5 mg twice daily. Statistical
signiﬁcance was determined using 2-tailed P values
(P < 0.05).
Results
Baseline characteristics
We identiﬁed 39,327 AF patients starting DOAC treatment, with 23,884 patients (55% females) who met the inclusion criteria (Fig. 1), with baseline characteristics as listed
in Table 1 and Supplemental Table S5. Before weighting,
females were older and had fewer comorbidities, indicated by
a lower mean Charlson comorbidity index (0.63 for women;
0.83 for men). Speciﬁcally, 73% of females, compared with
62% of males, were  75 years old. Apart from hypertension
(females, 79.1%; males, 75.1%), females had a lower prevalence, compared with males, of coronary artery disease (37.1%
vs 48.3%), diabetes (30.0% vs 37.6%), cancer (36.8% vs
45.2%), and alcoholism (0.5% vs 1.7%). Although baseline
stroke risk estimated by CHADS2 score (Congestive Heart
Failure, Hypertension, Age  75 years, Diabetes, and Prior
Stroke or Transient Ischemic Attack or Thromboembolism)
was higher in females than males (mean  SD: females, 2.81
 1.36; males, 2.63  1.43), the baseline bleeding risks as
determined by HAS-BLED score (Hypertension, Abnormal
Renal/Liver Function, Stroke History, Bleeding History
or Predisposition, Labile INR, Elderly (> 65 Years), Drugs
predisposing to bleeding and Alcohol use; labile
INR excluded) were similar (females, 2.45  0.96; males,
2.38  0.97). Apixaban was more commonly prescribed than
rivaroxaban (females, 60.8%; males, 58.1%). Although the
standard dosing regimens for both apixaban and rivaroxaban
were prescribed more frequently for males, a higher fraction of
females were prescribed the reduced apixaban dosing regimen.
Regarding co-medications, cytochrome P450 (CYP) 3A4/Pglycoprotein inhibitor or inducer prescriptions were balanced
between the sexes; statin prescription was more common for
males, and acetaminophen and proton pump inhibitor use
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were higher for females. Both sexes had similar numbers of
primary care visits, ED visits, and hospitalizations. However,
males had a higher prevalence of coronary angiography and
revascularization. Females had, on average, lower hemoglobin
level, serum creatinine level, and eGFR. After weighting,
baseline characteristics were well balanced between pseudocohorts (standardized difference < 10%), except for the
apixaban dosing regimen and the serum creatinine level, with
the latter intentionally not included in our propensity score
model.
Outcomes
The unweighted numbers of events recorded through
hospital encounters over a 90-day follow-up period are listed
in Figure 2. After weighting, the risk for major hemorrhage
associated with DOAC use in AF patients was similar for the
2 sexes (RR, 0.96; 95% CI, 0.81-1.15; females vs males).
With regard to stroke prevention, there was no difference in
the risk of ischemic stroke, SE, or TIA between female and
male patients (RR, 1.01; 95% CI, 0.86-1.19), a ﬁnding that
remained unchanged after excluding TIA (RR, 1.07; 95%
CI, 0.80-1.43). Similarly, no sex-related differences in these
outcomes were observed when repeating the above analyses
adjusting for dosing regimen (Supplemental Table S6).
Time-to-event analyses further corroborated our ﬁndings
(Fig. 3), indicating comparable risks for major bleeding
(hazard ratio [HR], 0.96; 95% CI, 0.80-1.15) and thromboembolic events (ischemic stroke, SE, or TIA; HR, 1.01;
95% CI, 0.86-1.18). Compared with males, females had a
lower risk for MI (RR, 0.66; 95% CI, 0.52-0.84; P ¼
0.0008) and all-cause mortality (RR, 0.76; 95% CI, 0.670.87; P < 0.0001; Fig. 2). In a subgroup analysis, primary
outcomes were compared between sexes after stratifying each
DOAC according to dosing regimen. Risks for major
bleeding and for stroke did not differ between females and
males on apixaban and rivaroxaban prescribed in either
normal or reduced doses (Fig. 4).
Discussion
In this analysis of administrative healthcare data from
23,884 elderly patients with newly treated AF receiving
routine care we assessed the association of sex with risks for
bleeding or thromboembolic events of rivaroxaban and apixaban treatment using propensity score weights that produced
well-balanced synthetic cohorts of females and males.
Compared to males, females had a similar 90-day risk for
major bleeding or stroke associated with a DOAC prescription, but they had a lower 90-day risk for MI and all-cause
mortality, after differences in baseline risk factors were
balanced.
To our knowledge, this is the ﬁrst population-based study
to perform a direct comparison between female and male
patients prescribed apixaban or rivaroxaban, to determine the
independent effect of sex on therapeutic and adverse outcomes. Previously, 2 population-based studies, one from
Canada30 and one from the United States,31 assessed sex
differences in dabigatran and rivaroxaban effectiveness and
safety, but a different approach was taken, as comparison was
made to another OAC treatment in AF patients of the same
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Table 1. Select baseline characteristics of study cohorts
Unweighted cohort
Characteristics
Age at index date, y
Age  75
DOAC type, mg daily
Apixaban
10
5
Rivaroxaban
20
15
Medical historyy
CHADS2 scorez
HAS-BLED scorex
Congestive heart failure
Hypertension
Diabetes
Prior ischemic stroke/systemic
embolism
Prior TIA
Chronic kidney disease
Chronic liver disease
Prior hemorrhage
Anemia
Alcoholism
CAD (incl. angina)
Prior myocardial infarction
Prior deep vein thrombosis
Prior pulmonary embolism
Cancer
Charlson comorbidity indexk
Medication history{
Anti-arrhythmic drugs
Clopidogrel
Other oral anti-platelets
Acetylsalicylic acid
NSAIDs
Corticosteroids
Statins
Proton pump inhibitors
CYP3A4/P-gp inducers**
CYP3A4/P-gp inhibitorsyy

Weighted cohort

Male (n ¼ 10,787)

Female (n ¼ 13,097)

Std. Diff*

Male (n ¼ 23,698)

Female (n ¼ 23,821)

Std. Diff*

77.6  7.4
6688 (62.0)

80.0  7.6
9591 (73.2)

0.31
0.24

78.8  11.3
16,057 (67.8)

78.9  10.3
16,242 (68.2)

0.01
0.01

4213 (39.1)
2055 (19.1)

4191 (32.0)
3778 (28.8)

0.15
0.23

9023 (38.1)
5057 (21.3)

7890 (33.1)
6318 (26.5)

0.10
0.12

3314 (30.7)
1205 (11.2)

3458 (26.4)
1670 (12.8)

0.10
0.05

6838 (28.9)
2781 (11.7)

6667 (28.0)
2945 (12.4)

0.02
0.02

2.63  1.43
2.38  0.97
3107 (28.8)
8096 (75.1)
4054 (37.6)
500 (4.6)

2.81  1.36
2.45  0.96
3669 (28.0)
10,355 (79.1)
3932 (30)
577 (4.4)

0.13
0.07
0.02
0.10
0.16
0.01

2.72  2.04
2.42  1.43
6713 (28.3)
18,249 (77.0)
8021 (33.8)
1057 (4.5)

2.73  1.91
2.42  1.31
6785 (28.5)
18,381 (77.2)
7996 (33.6)
1059 (4.4)

0.01
0.00
0.00
0.00
0.00
0.00

126 (1.2)
1117 (10.4)
458 (4.2)
610 (5.7)
2155 (20.0)
188 (1.7)
5209 (48.3)
841 (7.8)
36 (0.3)
50 (0.5)
4874 (45.2)
0.83  1.44

152 (1.2)
1095 (8.4)
420 (3.2)
666 (5.1)
2489 (19.0)
59 (0.5)
4853 (37.1)
728 (5.6)
57 (0.4)
91 (0.7)
4818 (36.8)
0.63  1.25

0
0.07
0.05
0.03
0.03
0.12
0.23
0.09
0.02
0.03
0.17
0.15

268 (1.1)
2194 (9.3)
888 (3.7)
1289 (5.4)
4,365 (19.6)
249 (1.0)
9988 (42.1)
1578 (6.7)
88 (0.4)
137 (0.6)
9746 (41.1)
0.73  1.98

275 (1.2)
2197 (9.2)
878 (3.7)
1289 (5.4)
4630 (19.4)
212 (0.9)
9964 (41.8)
1567 (6.6)
93 (0.4)
141 (0.6)
9721 (40.8)
0.73  1.86

0.01
0.00
0.00
0.00
0.01
0.01
0.01
0.00
0.00
0.00
0.01
0.00

0.01
0.09
0.02
0.03
0.05
0.02
0.18
0.11
0.03
0.06

791
2157
11,494
671
2559
6362
11,494
7228
151
2482

820
2161
11,472
668
2596
6388
11,472
7354
150
2532

0.01
0.00
0.01
0.00
0.00
0.00
0.01
0.01
0.00
0.00

380
1145
133
332
1080
2826
5772
3025
79
1053

(3.5)
(10.6)
(1.2)
(3.1)
(10.0)
(26.2)
(53.5)
(28.0)
(0.7)
(9.8)

446
1038
135
346
1505
3537
5817
4341
70
1513

(3.4)
(7.9)
(1.0)
(2.6)
(11.5)
(27.0)
(44.4)
(33.1)
(0.5)
(11.6)

(3.3)
(9.1)
(48.5)
(2.8)
(10.8)
(26.8)
(48.5)
(30.5)
(0.6)
(10.5)

(3.4)
(9.1)
(48.2)
(2.8)
(10.9)
(26.8)
(48.2)
(30.9)
(0.6)
(10.6)

Data are presented as n (%) or mean  standard deviation (SD). Boldface indicates a standardized difference  10%, which is considered meaningful.
CAD, coronary artery disease; CHADS2, Congestive Heart Failure, Hypertension, Age  75, Diabetes, and Prior Stroke/Transient Ischemic Attack; CYP3A4,
cytochrome P450 3A4; DOAC, direct oral anticoagulant; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition,
Labile INR, Elderly (> 65 Years), Drugs and Alcohol; incl., including; INR, international normalized ratio; NSAIDs, nonsteroidal anti-inﬂammatory drugs; P-gp,
P-glycoprotein; Std. Diff, standardized difference; TIA, transient ischemic attack.
* A standardized difference  10% is considered meaningful.
y
Medical history 5 years prior to index date.
z
CHADS2 score estimates ischemic stroke risk in non-anticoagulated patients. Score awards 1 point each for congestive heart failure, hypertension, diabetes, and
age  75 years, and 2 points for stroke/TIA/ thromboembolism.
x
HAS-BLED score estimates major bleeding risk for patients on anticoagulation. Score awards 1 point each for hypertension, abnormal renal function, abnormal
liver function, history of stroke, bleeding or anemia, labile INR, age > 65 years, medication usage predisposing to bleeding, and alcohol use; labile INR was excluded
as it is not monitored in these patients.
k
3-year look-back period for Charlson comorbidity index.
{
Co-medication use 120 days prior to index date.
** Carbamazepine/ phenobarbital/ phenytoin/ rifampin.
yy
Amiodarone/ clarithromycin/ cyclosporine/ diltiazem/ ketoconazole/ ritonavir/ verapamil.

sex (Supplemental Table S1). Therefore, results from these
studies cannot be compared to our ﬁndings.
In the current study, careful consideration was given to
adjusting for covariates between female and male AF patients
that may determine major bleeding or stroke risk in the
context of apixaban or rivaroxaban prescription. Using

propensity scores, weighted male and female synthetic cohorts
were created with a well-balanced distribution of such baseline
risk factors, including those considered sex-related, such as
stroke risk (higher in females) and MI risk (higher in males).32
We did not include characteristics that represent well-characterized physiological differences between sexes, including
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Figure 2. Risk ratios for the study outcomes. Male sex was used as the reference. CI, conﬁdence interval; TIA, transient ischemic attack.

hemoglobin level, serum creatinine level, and eGFR.33 Before
weighting, the estimated baseline stroke risk (CHADS2 score)
was higher in females, compared to males. This difference may
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Figure 3. Weighted Kaplan-Meier cumulative probability plots for (A)
major hemorrhage and (B) thromboembolic events. CI, conﬁdence
interval; TIA, transient ischemic attack.

be driven primarily by females being older and having a higher
prevalence of hypertension. The remaining stroke risk factors
were either similarly prevalent (congestive heart failure, history
of stroke) or less frequent among females (diabetes). Although
these sex-related differences are consistent with previous observations among AF patients,30,34,35 the Anticoagulation and
Risk Factors in Atrial Fibrillation (ATRIA) study (N ¼
13,559) found that females had a higher risk than males for
AF-related thromboembolism at both younger and older ages
that was independent of the presence of other risk factors for
stroke.34 In terms of bleeding risk, the difference in HASBLED scores was not considered meaningful. After weighting, these known predictors for stroke and bleeding were
equally distributed between the 2 cohorts.
Females with AF receiving anticoagulation treatment also
were shown to have a higher stroke risk than men, even after
adjustment for risk factors, as suggested by 2 prospective realworld studies, including the Global Anticoagulant Registry in
the Field-AF (GARFIELD-AF) registry (N ¼ 28,624)12,13
comprising predominantly patients on warfarin. We determined a comparable stroke risk between sexes among rivaroxaban and apixaban AF users in routine care. Previous
studies are limited to secondary analyses of randomized
controlled trial data, and they have reported conﬂicting results
(Supplemental Table S1). Similar stroke risks for women vs
men were reported in a subanalysis of apixaban and warfarin
users in the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)
trial and in a meta-analysis of large clinical trials, including
those evaluating dabigatran, rivaroxaban, and apixaban.14,17
In contrast, a higher risk of stroke among women taking
DOACs was reported in a subanalysis of the Apixaban Versus
Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for
Vitamin K Antagonist Treatment (AVERROES) trial and a
more recent meta-analysis of 5 trials also including edoxaban.15,18 However, some of the aforementioned studies did
not adjust for differences between the sexes in the baseline risk
for stroke (ie, higher CHADS2 scores in women); thus, their
ﬁndings may not reﬂect the independent effect of a patient’s
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Figure 4. Risk ratios of primary outcomes stratiﬁed by pre-speciﬁed subgroups. Male sex was used as the reference. CI, conﬁdence interval; TIA,
transient ischemic attack.

sex but rather the result of differences in risk factors for stroke
between women and men, revealing another critical aspect of
treatment.
Our ﬁndings suggest comparable risks for females and
males for major bleeding, thus mostly corroborating the
ﬁndings from clinical trials indicating lower or similar risk in
females compared to males.15-18 This ﬁnding was further
supported by subgroup analyses according to DOAC type
(apixaban, rivaroxaban) and dosing regimen (standard,
reduced) that did not show signiﬁcant differences in major
bleeding events between sexes, including for gastrointestinal
and intracranial hemorrhage. Although females prescribed
apixaban were reported to have about a 15% higher blood
exposure, compared to males, after adjusting for dose, body
weight, and renal function,20 this study suggests that the effect
of sex on apixaban concentration does not translate into
increased bleeding risk.
In this study, female patients had a 24% lower risk of allcause death, compared with the risk for male patients. This
ﬁnding coincides with results from the ARISTOTLE trial,
which reported a 35% lower risk for all-cause mortality in females.14 However, this result is less likely related to sex differences in the effect of DOACs among AF patients than to an
overall higher mortality rate in males, compared with that for
females, that is seen in the general population of Canada.36 AF
has been associated with an increased risk of death in both males
and females,2 though the risk is stronger in females. According
to a recent meta-analysis of cohort studies (N ¼ 4,371,714), AF
is associated with a 12% greater risk of all-cause mortality in
females compared to males.37 To more appropriately determine
the effect of sex on DOAC-associated mortality in AF patients,
future studies require inclusion of data for similarly aged

non-AF patients in their analysis, to control for sex differences
in mortality rate within the general population. Similarly, the
34% adjusted lower risk of MI among females likely is not due
to a sex-speciﬁc DOAC effect. Adjusting for baseline characteristics included risk factors for coronary artery disease; thus,
differences in risk likely reﬂect the independent association of
female sex with lower MI incidence reported in the general
population.32
Dose reductions are recommended when prescribing rivaroxaban in patients with impaired renal function, and with
apixaban prescription when patients meet at least 2 of the
following criteria: impaired renal function, old age, and low
body weight.21,22 Although we were not able to access weight
data, female patients in our study were older, had a higher serum
creatinine level, and had a lower eGFR, compared to those for
men. With increased age, renal function declines, and this effect
is even more pronounced among females.38 Accordingly, more
females in our study received a reduced dose of rivaroxaban and
apixaban, compared to the number of males (41.6% of females
vs 30.3% of males), a difference previously reported for dabigatran users.30 Therefore, we also assessed the effect of sex on
our primary outcomes, according to dosing regimen, in a subgroup analysis, which did not indicate sex differences in major
bleeding or stroke for AF patients on apixaban or rivaroxaban
with reduced or normal doses.
Although our study population was large, reﬂecting routine
care-prescribing practices and highlighting the generalizability
of our work, the following limitations should be acknowledged. Despite our use of a robust method to balance cohorts
using propensity score weights, residual confounding still
might have been present. This approach allowed us to
maintain a large sample size, as opposed to a propensity
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score-matching method, which would have excluded about
75% of patients. DOAC exposure was determined based on
ﬁlling of prescriptions, with no information available on
therapy adherence. Due to the limited number of events, TIA
was included as a primary outcome with ischemic stroke and
SE, despite the potential for misclassiﬁcation. However, our
results were unchanged when the outcome was evaluated with
TIA excluded. Similarly, bleeding events included, among
other types, gastrointestinal and intracranial hemorrhage;
however, exploratory results indicate no increased risks for
these speciﬁc subtypes in females vs males (Supplemental
Table S7). Lastly, considering the chronic nature of AF and
the long-term use of these agents, a potential association of sex
with these events after 90 days cannot be ruled out, owing to
the relatively short duration of follow-up.
Our ﬁndings indicate similar 90-day risks for ischemic
stroke and hemorrhage leading to an ED visit or hospitalization in older female and male AF patients prescribed apixaban
or rivaroxaban. Accordingly, sex-dependent differential effects
for these clinical outcomes were not observed in elderly AF
patients using current dosing schemes in routine care.
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